Tocilizumab in Covid-19

To the Editor: Stone et al. (Dec. 10 issue) 1 report that tocilizumab had no significant effect on the risk of intubation or death in moderately ill patients hospitalized with coronavirus disease 2019 (Covid-19). These results should not be extrapolated to other populations of patients with Covid-19, particularly the critically ill. Our multicenter cohort study involving 3924 critically ill patients with Covid-19 showed that early administration of tocilizumab was associated with prolonged survival. 2 The patients enrolled in our study were fundamentally different from those in the trial by Stone et al. (